Source-checked guide

How to Get Oral GLP-1: 5 Prescription Checks for 2026

By the Clinic Scout Editorial Team · Updated October 12, 2026

Sources current as of 2026-10-09 · Prices checked 2026-10-09 – 2026-10-09 · Prices and terms can change.

If you are researching how to get oral GLP-1 medicines, start with a clinician, identify the exact prescription product, then confirm coverage and pharmacy fulfilment. Wegovy tablets, Foundayo and diabetes-labeled semaglutide tablets have different indications and instructions. An online consultation or advertised price does not establish personal eligibility. [S1][S2][S3][S4]

About this guide and its limits

**Sources checked October 9, 2026.** Clinic Scout is an independent comparison publisher, not a clinic, pharmacy or insurer. We explain the access process and compare reported information; we do not prescribe, decide whether you qualify, or choose a treatment. This page contains no affiliate purchase links and collects no health or contact information. The worksheet below is available on the page, not by email.

The most useful first distinction is between access and treatment suitability. Access questions include who evaluates you, which product is prescribed, how a pharmacy receives the prescription and what a payment quote includes. Treatment questions include whether a medicine is appropriate, which regimen to use and how to monitor it. Take the second group to the prescribing clinician rather than trying to solve it with a comparison table.

Our five checks are a discussion framework, not steps that guarantee approval. You can use them with an existing clinician, a specialist or a telehealth service you independently assess. The purpose is to leave each conversation knowing the next responsible party and what remains unconfirmed.

Check 1: Identify the exact pill, not just “oral GLP-1”

The current manufacturer-hosted US labels describe several oral products. Wegovy tablets contain semaglutide. Foundayo tablets contain orforglipron. The combined diabetes prescribing information covers Rybelsus and Ozempic tablets, which also contain semaglutide. These names do not establish identical indications, strengths or administration instructions. **Prescribing information, physical page 1 of each document.** [S1][S2][S3]

Ask the clinician to write down the product name and formulation when discussing options. “Ozempic” without the word tablet or injection can leave a practical ambiguity; the current combined tablet label explicitly distinguishes tablets from injections. It also states that Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis. Do not convert between them using the number printed on a package. **Combined tablet label, physical page 1.** [S2]

Wegovy's combined label likewise separates tablet and injection indications. Its injection section includes pediatric and liver-disease indications that are not repeated in the tablet indication section. A general page about the brand can therefore be too broad for an oral-product question. Ask which exact formulation and indication the clinician is discussing. **Wegovy label, physical page 1.** [S1]

The captured competitor explainer's product-list takeaway names Rybelsus, Wegovy pill and Foundayo. That describes its wording, not a medical inventory inferred from headings. Separately, the primary diabetes label identifies Ozempic tablets as well as Rybelsus. [S11][S2]

How the receptor mechanism and blood-sugar evidence differ.

Semaglutide binds to and activates the GLP-1 receptor. The diabetes-tablet label describes glucose-dependent insulin stimulation and glucagon reduction, with a minor delay in early post-meal gastric emptying. This explains the mechanism, not an individual's response. **Combined tablet label, section 12.1, physical page 6.** [S12]

Foundayo contains a different active ingredient, orforglipron, whose label also identifies it as a GLP-1 receptor agonist. Sharing a receptor class does not make its instructions or evidence interchangeable with semaglutide tablets. **Foundayo label, physical page 1.** [S3]

The combined diabetes label bases Rybelsus and Ozempic-tablet glycemic effectiveness on controlled Rybelsus studies in adults with type 2 diabetes. In its 26-week double-blind randomized monotherapy trial, adults inadequately controlled with diet and exercise received semaglutide tablets or placebo; the 7 mg and 14 mg study groups had statistically significant HbA1c reductions versus placebo. These are diabetes study regimens, not strength-selection, conversion or weight-loss instructions. **Combined tablet label, sections 14.1–14.2, physical page 7.** [S12]

Check 1: Identify the exact pill, not just “oral GLP-1”
Product named in the current label	What the label establishes
Wegovy tablets	With a reduced-calorie diet and increased physical activity, the tablets are indicated for long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition; a separate indication concerns major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Physical page 1. [S1]
Foundayo tablets	With a reduced-calorie diet and increased physical activity, the label describes long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition. This is the orforglipron product, not semaglutide. Physical page 1. [S3]
Rybelsus and Ozempic tablets	Their combined label describes glycemic control with diet and exercise in adults with type 2 diabetes, and reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. Physical page 1. [S2]

Check 2: Arrange an evaluation, not a promised prescription

Wegovy's official access page describes three practical stages: talk to a doctor, investigate savings and fill the prescription. It explicitly states that Wegovy requires a prescription and points readers toward both in-person and telehealth care resources. Those resources are navigation options, not an independent assessment by Clinic Scout of any listed service. [S4]

Yale Medicine's access overview says patients can begin with a primary care clinician, an obesity-medicine specialist or, in some cases, a telehealth provider. It emphasizes experience and follow-up over time. That supports asking about continuity of care rather than choosing solely by the shortest advertised appointment time. It does not establish the licensing, availability or quality of a particular online provider. [S6]

Before booking, ask the service what the consultation covers and what happens if the clinician does not recommend the requested medicine. Useful questions include whether an existing prescriber can handle the evaluation, who reviews your medication history, whether additional information is needed, and how questions are handled afterward. These are questions to clarify the service, not a list of universal requirements or a prediction about your assessment.

Prepare a private medication list and questions for the clinical appointment, including other prescriptions, supplements and relevant medical history. The labels describe interactions and contraindications that require product-specific assessment. For example, the semaglutide labels discuss possible effects on other oral medicines, while Foundayo's label also identifies specific drug-interaction categories. **Physical page 1 of each label.** [S1][S2][S3]

Do not send that personal information to us. Use the clinician's appropriate secure process after verifying the destination. This guide can help you organize questions, but it is not a screening form and does not need your weight, diagnosis, medication list, insurance number or identity documents.

If you already receive care for diabetes or another condition, ask how the proposed service would communicate with your existing care team. If an online service describes an ongoing membership, request the written cancellation and follow-up terms before payment. We have not established any specific service's fees or refund rights here, so do not read these questions as a claim that a refund or prescription is available.

Label risks remain important when the medicine is a pill

An oral formulation does not remove the need for a clinical risk review. Wegovy and the Rybelsus/Ozempic tablet label contain boxed warnings about thyroid C-cell tumors observed with semaglutide in rodents, with human relevance not determined. They list personal or family history of medullary thyroid carcinoma and MEN 2 among contraindications, alongside the specified hypersensitivity restrictions. **Physical page 1 of the respective labels.** [S1][S2]

Foundayo also has a boxed warning and contraindications involving personal or family history of medullary thyroid carcinoma and MEN 2. Its warning is not identical to semaglutide's: it explains that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, while the human relevance of GLP-1-receptor-dependent rodent findings remains undetermined. Avoid collapsing those distinct label statements into one claim about all drugs. **Foundayo label, physical page 1.** [S3]

The labels also describe significant gastrointestinal, pancreatic, gallbladder, kidney, hypoglycemia and hypersensitivity risks or precautions, with product-specific wording. These summaries are not the complete safety information and do not determine whether a reader can take a medicine. Ask the clinician to review the complete current label and explain which warnings are relevant to your history. **Physical page 1 of each document.** [S1][S2][S3]

Pregnancy, breastfeeding, planned procedures and other medicines belong in that conversation. The labels contain different reproductive and procedural precautions; they should not be compressed into a universal instruction about stopping, switching or timing medicines. We do not provide an individualized plan for any of those situations. **Physical page 1 of each label.** [S1][S2][S3]

A practical way to finish the appointment is to ask, “Which instructions should I follow, which symptoms or problems should I contact you about, and how can I reach the clinical team?” That leaves the actual guidance with the person responsible for your care rather than with a marketing page or an online discussion.

Read warning categories precisely.

A contraindication is not the same heading as a warning or precaution. For example, the labels place personal or family history of medullary thyroid carcinoma and MEN 2 in the contraindications section, while discussing several other conditions under warnings and precautions. A comparison article should not silently move a condition between those categories or replace the named thyroid-cancer type with every possible thyroid diagnosis. **Physical page 1 of the respective labels.** [S1][S2][S3]

That distinction is a reason to bring accurate records and specific questions to the appointment, not to decide for yourself that a warning is unimportant. Ask which document the clinician is using, whether it covers the exact oral product, and where you can read the complete patient information afterward. If a short website summary appears inconsistent with that information, ask the clinician or pharmacist to explain the difference. We cannot adjudicate a personal medical history from a search phrase, and a label excerpt cannot replace the full clinical assessment.

Check 3: Separate coverage, savings and self-pay

NovoCare Pharmacy's published Wegovy-tablet self-pay prices were **current as of 2026-10-09**. The amounts below are medication prices for the stated tablet strength and supply, not a personal quote or total care cost. [S5]

Eligibility and restrictions apply. Novo Nordisk reserves the right to modify or cancel the programme at any time. These are the published 2026-10-09 terms, not a guarantee of your next fill; separately quoted consultation, membership or other care charges are not established by this medication-price table. [S5]

Mark unconfirmed personal quotes “unknown,” not zero. Published self-pay prices do not establish insurance benefits.

For broader cost-and-label context, see the cluster's Wegovy pills and oral semaglutide cost guide.

See the oral GLP-1 insurance coverage guide and insurance support versus coverage guide for those separate questions; neither establishes your benefit.

For a savings offer, check the official product-specific terms separately from the self-pay prices above. NovoCare's page distinguishes insurance and self-pay pathways; these payment routes do not have interchangeable conditions. [S5]

See the patient assistance versus savings guide for that distinction. Do not change treatment to chase a price without discussing it with the prescriber.

Medicare oral-product access is a separate pathway.

CMS's Medicare GLP-1 Bridge information, checked **2026-10-09**, describes a July 1, 2026–December 31, 2027 demonstration outside ordinary Part D coverage and payment flows. Listed weight-management products include Wegovy tablets and Foundayo. Eligible Part D plan types, clinical criteria, a prescription and prescriber prior authorization are required; Medicare enrollment alone does not establish eligibility. [S13]

CMS directs Part D-covered indications, such as type 2 diabetes, through the Part D plan instead of the Bridge. Identify the oral product, indication and programme together: conditional Bridge access is neither universal oral-GLP-1 coverage nor a manufacturer self-pay offer. [S13]

Check 3: Separate coverage, savings and self-pay
Wegovy tablet strength	Published self-pay medication price
1.5 mg	$149 for one bottle of 30 tablets. [S5]
4 mg	$199 for one bottle of 30 tablets. [S5]
9 mg or 25 mg	$299 for one bottle of 30 tablets. [S5]

Check 3: Separate coverage, savings and self-pay
Question to ask	What to record
What is covered?	The exact product and presentation, and who confirmed the answer.
What would this fill cost?	The supply period, quoted amount and whether insurance or a self-pay arrangement is being used.
What changes next time?	Any introductory period, different package, savings limit or programme condition that could change the quote.
What is outside the drug price?	Any separately quoted consultation, membership, delivery or other charge.
What remains unresolved?	The missing information and the responsible clinician, insurer, pharmacy or programme contact.

Check 4: Confirm the prescription and pharmacy handoff

The official Wegovy access page describes filling a prescription through a local pharmacy or using delivery, subject to terms. NovoCare's pharmacy page describes having the prescriber send the prescription and looking for a confirmation message. These are reported fulfilment pathways, not proof that a particular pharmacy has your product available or that a shipment has been approved. [S4][S5]

Ask who sends the prescription, which pharmacy receives it and how you will recognize the next legitimate communication. A clinical visit, a transmitted prescription and a completed pharmacy transaction are different stages. Request confirmation of the stage you are actually at rather than interpreting every account notification as approval to start treatment.

At the pharmacy, clarify the exact name, formulation, package and written instructions on the prescription. If any of those differ from what you discussed with the clinician, ask the pharmacy and clinician to reconcile them before relying on a comparison page. We cannot determine from a photo, a product nickname or a checkout description whether a particular prescription is correct.

The current Rybelsus/Ozempic tablet label expressly warns against milligram-for-milligram substitution. Wegovy's label has separate tablet and injection instructions. These are concrete reasons not to infer a replacement regimen from a similar active ingredient or a similar number on a box. **Diabetes tablet and Wegovy labels, physical page 1.** [S1][S2]

For delivery, ask the pharmacy about the actual expected timing, any remaining authorization and the contact for a delayed or damaged order. We have not verified a delivery time or universal replacement policy. If a prescription cannot be filled, the next question is which responsible party can explain the specific obstacle, not which unverified website promises the fastest workaround.

Keep the medicine's own supplied information and the pharmacy contact available. A later change to product instructions, availability or price should be resolved with the relevant source. A saved search snippet or an old comparison screenshot does not establish the terms of a new fill.

Check 5: Discuss daily-use fit and ongoing follow-up

The labels differ in how tablets are taken. Wegovy and the Rybelsus/Ozempic tablet label describe morning administration on an empty stomach with water and a waiting period before food, beverages or other oral medicines. Foundayo's label describes once-daily use with or without food. These are product-label distinctions to discuss, not a recommendation to choose one medicine over another. **Physical page 1 of each label.** [S1][S2][S3]

Ask the clinician or pharmacist to explain the complete instructions for the actual prescription and how they fit with your other medicines and routine. Do not derive a switching, escalation or missed-tablet plan from this guide. The label's instructions are not interchangeable, and your clinical team should address questions about the prescribed regimen.

Also ask what follow-up is included, who reviews tolerability or other concerns, and how a future change in insurance or supply would be handled. Yale Medicine's access overview emphasizes a clinician who can follow the patient over time. That supports planning for communication beyond the first visit; it is not proof that every service provides the same level of support. [S6]

If affordability or daily-use practicalities are a concern, raise them before making a commitment. A useful conversation separates “Can I obtain this prescription?” from “How would we manage the practical issues that may arise afterward?” We do not supply answers about personal treatment duration or a stop-and-restart strategy.

Long-term treatment and stopping are different evidence questions.

Wegovy-tablet and Foundayo labels describe reducing excess body weight and maintaining weight reduction long term. They do not establish a universal short course or an individual treatment duration. **Physical page 1 of both labels.** [S1][S3]

In the STEP 4 randomized withdrawal trial, adults with overweight or obesity without diabetes who reached subcutaneous semaglutide 2.4 mg weekly after a 20-week run-in continued treatment or switched to placebo for 48 weeks, with lifestyle intervention in both groups. Continued treatment produced further average weight loss; the placebo-switch group regained weight. Gastrointestinal events were more frequent with continued treatment. This selected-participant injection trial does not predict how much or how quickly weight returns after stopping oral tablets, or supply individual stopping, restarting or lifelong-treatment instructions. [S14]

What oral-semaglutide studies can and cannot tell you

The OASIS 4 randomized, double-blind trial studied oral semaglutide 25 mg against placebo with lifestyle interventions in adults with overweight or obesity without diabetes. At the week-64 assessment, the oral-semaglutide group had greater mean weight reduction, but gastrointestinal adverse events were more common than with placebo. The study was funded by Novo Nordisk. This qualitative result applies to that product, population, comparison and study period; it is not an individual forecast. [S7]

OASIS 1 studied a different oral-semaglutide amount, 50 mg, for 68 weeks in adults without type 2 diabetes and also reported greater weight reduction than placebo alongside more gastrointestinal adverse events. OASIS 2 used 50 mg in an East Asian population with different entry criteria and included participants with type 2 diabetes. Those studies do not turn a 50 mg research regimen into instructions for a currently prescribed product. [S8][S9]

These trials were not a head-to-head comparison of every pill and injection named on this page. Do not rank products by placing percentages from different trials side by side without considering the populations, design and analysis. The captured OASIS 4 registration and protocol identify the planned study; observed outcomes here come from the published original report, not from the mere existence of a registration. [S7][S8][S9][S10]

The evidence also does not establish the performance of a provider, a savings programme or a differently formulated compounded product. We have not retrieved product-matched evidence that would justify transferring these results to those settings. The diabetes-tablet evidence above concerns glycemic control, not these OASIS weight-management outcomes. For cardiovascular effects or a different formulation, use the evidence relevant to the actual treatment rather than extrapolating from a weight-management study.

Your on-page appointment and pharmacy checklist

Use this as a private note for your own conversations, not as information to submit to Clinic Scout. Do not post prescriptions, medical records or insurance identifiers in public comments to obtain an unofficial eligibility answer. We do not operate a patient-support service or verify individual prescriptions.

Your on-page appointment and pharmacy checklist
Before relying on an answer	Write down
Product discussion	Exact brand and whether the prescription is for tablets or injections.
Clinical evaluation	Who evaluates suitability and who supplies the treatment instructions.
Payment discussion	Insurance or self-pay route, supply period, full quote and unresolved conditions.
Pharmacy handoff	Destination pharmacy, confirmation stage and contact for questions.
Follow-up	Clinical contact, what support was described and which questions remain open.

Methodology and update policy

The Clinic Scout Editorial Team checked current manufacturer-hosted US prescribing information, official access and pharmacy pages, and the cited PubMed originals on October 9, 2026. We compared the exact-query search results for reader questions, not for medical authority. The original physical PDF pages were inspected before parsing; label page references above refer to those original documents, not a renumbered extract.

Our editorial guidelines explain organization-only attribution and our comparison role. This article is not a medical signoff or a personal eligibility determination. Programme prices, stock, provider availability and individual insurance decisions remain unverified unless expressly stated otherwise; this guide does not quote a personal treatment total.

We will revisit this guide when product labels, official access pathways or programme terms change. That is an update policy, not a claim that future rechecks have happened. Before relying on an instruction or payment offer, return to the current official document and the responsible clinician, pharmacy or insurer. Keep the source date attached when sharing a summary.

Frequently asked questions

Can I get an oral GLP-1 without a prescription?

The official access material says Wegovy requires a prescription, and NovoCare says the products on its pharmacy page require one. Start with a clinical evaluation rather than treating a sales page as a prescription decision. This guide does not endorse sellers offering a shortcut around that process. [S4][S5]

Are Wegovy tablets the same as Rybelsus?

Both contain semaglutide, but the current labels describe different products and indications. Wegovy tablets have adult weight-management and specified cardiovascular indications; the combined Rybelsus/Ozempic tablet label describes type 2 diabetes and its specified cardiovascular population. **Physical page 1 of both labels.** [S1][S2]

Does an online visit guarantee I can get the pill I want?

No personal prescription approval is established by this guide. The access pathway begins with a clinician, and the medicine remains prescription-only. Ask the service what an evaluation covers and what happens when the requested medicine is not prescribed; we have not verified a universal refund or outcome policy. [S4]

Are pills automatically easier or safer than injections?

That conclusion is not established here. The current oral labels contain significant warnings, contraindications and different administration requirements. Discuss the product-specific balance and practical instructions with the clinician rather than inferring safety from the absence of an injection. **Label highlights, physical page 1.** [S1][S2][S3]

Does the lowest advertised price show my long-term cost?

No individual cost is verified here. The manufacturer pharmacy page separates payment routes and attaches conditions to advertised amounts. Ask for the exact supply, product, payment arrangement and next-fill terms, plus any service charges quoted separately. [S5]

Can I use trial results to choose a dose or switch brands?

The cited trials studied defined regimens and populations; they are not a personal prescribing plan. In particular, the combined Rybelsus/Ozempic tablet label rejects milligram-for-milligram substitution. Take switching or regimen questions to the prescriber and pharmacist. **Combined tablet label, physical page 1.** [S2][S7][S8][S9]

What to verify

Confirm

Uses current primary evidence.
Separates verified facts from unknowns.
Maps decision-bearing claims to captured source text.

Do not assume

Terms, prices, labels, and coverage can change.
Individual outcomes and eligibility cannot be inferred from general evidence.
The page cannot replace clinician, plan, or pharmacy verification.

Verified claims

Each statement below is bound to its numbered source.

Open the claim-to-source map (42 claims)

> **Quick answer:** If you are researching how to get oral GLP-1 medicines, start with a clinician, identify the exact prescription product, then confirm coverage and pharmacy fulfilment. Wegovy tablets, Foundayo and diabetes-labeled semaglutide tablets have different indications and instructions. An online consultation or advertised price does not establish personal eligibility. [S1][S2][S3][S4]¹²³⁵
The current manufacturer-hosted US labels describe several oral products. Wegovy tablets contain semaglutide. Foundayo tablets contain orforglipron. The combined diabetes prescribing information covers Rybelsus and Ozempic tablets, which also contain semaglutide. These names do not establish identical indications, strengths or administration instructions. **Prescribing information, physical page 1 of each document.** [S1][S2][S3]¹²³
| Wegovy tablets | With a reduced-calorie diet and increased physical activity, the tablets are indicated for long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition; a separate indication concerns major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Physical page 1. [S1] |¹
| Foundayo tablets | With a reduced-calorie diet and increased physical activity, the label describes long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition. This is the orforglipron product, not semaglutide. Physical page 1. [S3] |³
| Rybelsus and Ozempic tablets | Their combined label describes glycemic control with diet and exercise in adults with type 2 diabetes, and reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. Physical page 1. [S2] |²
Ask the clinician to write down the product name and formulation when discussing options. “Ozempic” without the word tablet or injection can leave a practical ambiguity; the current combined tablet label explicitly distinguishes tablets from injections. It also states that Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis. Do not convert between them using the number printed on a package. **Combined tablet label, physical page 1.** [S2]²
Wegovy's combined label likewise separates tablet and injection indications. Its injection section includes pediatric and liver-disease indications that are not repeated in the tablet indication section. A general page about the brand can therefore be too broad for an oral-product question. Ask which exact formulation and indication the clinician is discussing. **Wegovy label, physical page 1.** [S1]¹
The captured competitor explainer's product-list takeaway names Rybelsus, Wegovy pill and Foundayo. That describes its wording, not a medical inventory inferred from headings. Separately, the primary diabetes label identifies Ozempic tablets as well as Rybelsus. [S11][S2]¹¹²
Wegovy's official access page describes three practical stages: talk to a doctor, investigate savings and fill the prescription. It explicitly states that Wegovy requires a prescription and points readers toward both in-person and telehealth care resources. Those resources are navigation options, not an independent assessment by Clinic Scout of any listed service. [S4]⁵
Yale Medicine's access overview says patients can begin with a primary care clinician, an obesity-medicine specialist or, in some cases, a telehealth provider. It emphasizes experience and follow-up over time. That supports asking about continuity of care rather than choosing solely by the shortest advertised appointment time. It does not establish the licensing, availability or quality of a particular online provider. [S6]⁷
Prepare a private medication list and questions for the clinical appointment, including other prescriptions, supplements and relevant medical history. The labels describe interactions and contraindications that require product-specific assessment. For example, the semaglutide labels discuss possible effects on other oral medicines, while Foundayo's label also identifies specific drug-interaction categories. **Physical page 1 of each label.** [S1][S2][S3]¹²³
An oral formulation does not remove the need for a clinical risk review. Wegovy and the Rybelsus/Ozempic tablet label contain boxed warnings about thyroid C-cell tumors observed with semaglutide in rodents, with human relevance not determined. They list personal or family history of medullary thyroid carcinoma and MEN 2 among contraindications, alongside the specified hypersensitivity restrictions. **Physical page 1 of the respective labels.** [S1][S2]¹²
Foundayo also has a boxed warning and contraindications involving personal or family history of medullary thyroid carcinoma and MEN 2. Its warning is not identical to semaglutide's: it explains that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, while the human relevance of GLP-1-receptor-dependent rodent findings remains undetermined. Avoid collapsing those distinct label statements into one claim about all drugs. **Foundayo label, physical page 1.** [S3]³
The labels also describe significant gastrointestinal, pancreatic, gallbladder, kidney, hypoglycemia and hypersensitivity risks or precautions, with product-specific wording. These summaries are not the complete safety information and do not determine whether a reader can take a medicine. Ask the clinician to review the complete current label and explain which warnings are relevant to your history. **Physical page 1 of each document.** [S1][S2][S3]¹²³
Pregnancy, breastfeeding, planned procedures and other medicines belong in that conversation. The labels contain different reproductive and procedural precautions; they should not be compressed into a universal instruction about stopping, switching or timing medicines. We do not provide an individualized plan for any of those situations. **Physical page 1 of each label.** [S1][S2][S3]¹²³
A contraindication is not the same heading as a warning or precaution. For example, the labels place personal or family history of medullary thyroid carcinoma and MEN 2 in the contraindications section, while discussing several other conditions under warnings and precautions. A comparison article should not silently move a condition between those categories or replace the named thyroid-cancer type with every possible thyroid diagnosis. **Physical page 1 of the respective labels.** [S1][S2][S3]¹²³
NovoCare Pharmacy's published Wegovy-tablet self-pay prices were **current as of 2026-10-09**. The amounts below are medication prices for the stated tablet strength and supply, not a personal quote or total care cost. [S5]⁶
For a savings offer, check the official product-specific terms separately from the self-pay prices above. NovoCare's page distinguishes insurance and self-pay pathways; these payment routes do not have interchangeable conditions. [S5]⁶
The official Wegovy access page describes filling a prescription through a local pharmacy or using delivery, subject to terms. NovoCare's pharmacy page describes having the prescriber send the prescription and looking for a confirmation message. These are reported fulfilment pathways, not proof that a particular pharmacy has your product available or that a shipment has been approved. [S4][S5]⁵⁶
The current Rybelsus/Ozempic tablet label expressly warns against milligram-for-milligram substitution. Wegovy's label has separate tablet and injection instructions. These are concrete reasons not to infer a replacement regimen from a similar active ingredient or a similar number on a box. **Diabetes tablet and Wegovy labels, physical page 1.** [S1][S2]¹²
The labels differ in how tablets are taken. Wegovy and the Rybelsus/Ozempic tablet label describe morning administration on an empty stomach with water and a waiting period before food, beverages or other oral medicines. Foundayo's label describes once-daily use with or without food. These are product-label distinctions to discuss, not a recommendation to choose one medicine over another. **Physical page 1 of each label.** [S1][S2][S3]¹²³
Also ask what follow-up is included, who reviews tolerability or other concerns, and how a future change in insurance or supply would be handled. Yale Medicine's access overview emphasizes a clinician who can follow the patient over time. That supports planning for communication beyond the first visit; it is not proof that every service provides the same level of support. [S6]⁷
The OASIS 4 randomized, double-blind trial studied oral semaglutide 25 mg against placebo with lifestyle interventions in adults with overweight or obesity without diabetes. At the week-64 assessment, the oral-semaglutide group had greater mean weight reduction, but gastrointestinal adverse events were more common than with placebo. The study was funded by Novo Nordisk. This qualitative result applies to that product, population, comparison and study period; it is not an individual forecast. [S7]⁸
OASIS 1 studied a different oral-semaglutide amount, 50 mg, for 68 weeks in adults without type 2 diabetes and also reported greater weight reduction than placebo alongside more gastrointestinal adverse events. OASIS 2 used 50 mg in an East Asian population with different entry criteria and included participants with type 2 diabetes. Those studies do not turn a 50 mg research regimen into instructions for a currently prescribed product. [S8][S9]⁹¹⁰
These trials were not a head-to-head comparison of every pill and injection named on this page. Do not rank products by placing percentages from different trials side by side without considering the populations, design and analysis. The captured OASIS 4 registration and protocol identify the planned study; observed outcomes here come from the published original report, not from the mere existence of a registration. [S7][S8][S9][S10]⁸⁹¹⁰⁴
The official access material says Wegovy requires a prescription, and NovoCare says the products on its pharmacy page require one. Start with a clinical evaluation rather than treating a sales page as a prescription decision. This guide does not endorse sellers offering a shortcut around that process. [S4][S5]⁵⁶
Both contain semaglutide, but the current labels describe different products and indications. Wegovy tablets have adult weight-management and specified cardiovascular indications; the combined Rybelsus/Ozempic tablet label describes type 2 diabetes and its specified cardiovascular population. **Physical page 1 of both labels.** [S1][S2]¹²
No personal prescription approval is established by this guide. The access pathway begins with a clinician, and the medicine remains prescription-only. Ask the service what an evaluation covers and what happens when the requested medicine is not prescribed; we have not verified a universal refund or outcome policy. [S4]⁵
That conclusion is not established here. The current oral labels contain significant warnings, contraindications and different administration requirements. Discuss the product-specific balance and practical instructions with the clinician rather than inferring safety from the absence of an injection. **Label highlights, physical page 1.** [S1][S2][S3]¹²³
No individual cost is verified here. The manufacturer pharmacy page separates payment routes and attaches conditions to advertised amounts. Ask for the exact supply, product, payment arrangement and next-fill terms, plus any service charges quoted separately. [S5]⁶
The cited trials studied defined regimens and populations; they are not a personal prescribing plan. In particular, the combined Rybelsus/Ozempic tablet label rejects milligram-for-milligram substitution. Take switching or regimen questions to the prescriber and pharmacist. **Combined tablet label, physical page 1.** [S2][S7][S8][S9]²⁸⁹¹⁰
| 1.5 mg | $149 for one bottle of 30 tablets. [S5] |⁶
| 4 mg | $199 for one bottle of 30 tablets. [S5] |⁶
| 9 mg or 25 mg | $299 for one bottle of 30 tablets. [S5] |⁶
Eligibility and restrictions apply. Novo Nordisk reserves the right to modify or cancel the programme at any time. These are the published 2026-10-09 terms, not a guarantee of your next fill; separately quoted consultation, membership or other care charges are not established by this medication-price table. [S5]⁶
Semaglutide binds to and activates the GLP-1 receptor. The diabetes-tablet label describes glucose-dependent insulin stimulation and glucagon reduction, with a minor delay in early post-meal gastric emptying. This explains the mechanism, not an individual's response. **Combined tablet label, section 12.1, physical page 6.** [S12]¹²
Foundayo contains a different active ingredient, orforglipron, whose label also identifies it as a GLP-1 receptor agonist. Sharing a receptor class does not make its instructions or evidence interchangeable with semaglutide tablets. **Foundayo label, physical page 1.** [S3]³
The combined diabetes label bases Rybelsus and Ozempic-tablet glycemic effectiveness on controlled Rybelsus studies in adults with type 2 diabetes. In its 26-week double-blind randomized monotherapy trial, adults inadequately controlled with diet and exercise received semaglutide tablets or placebo; the 7 mg and 14 mg study groups had statistically significant HbA1c reductions versus placebo. These are diabetes study regimens, not strength-selection, conversion or weight-loss instructions. **Combined tablet label, sections 14.1–14.2, physical page 7.** [S12]¹²
CMS's Medicare GLP-1 Bridge information, checked **2026-10-09**, describes a July 1, 2026–December 31, 2027 demonstration outside ordinary Part D coverage and payment flows. Listed weight-management products include Wegovy tablets and Foundayo. Eligible Part D plan types, clinical criteria, a prescription and prescriber prior authorization are required; Medicare enrollment alone does not establish eligibility. [S13]¹³
CMS directs Part D-covered indications, such as type 2 diabetes, through the Part D plan instead of the Bridge. Identify the oral product, indication and programme together: conditional Bridge access is neither universal oral-GLP-1 coverage nor a manufacturer self-pay offer. [S13]¹³
Wegovy-tablet and Foundayo labels describe reducing excess body weight and maintaining weight reduction long term. They do not establish a universal short course or an individual treatment duration. **Physical page 1 of both labels.** [S1][S3]¹³
In the STEP 4 randomized withdrawal trial, adults with overweight or obesity without diabetes who reached subcutaneous semaglutide 2.4 mg weekly after a 20-week run-in continued treatment or switched to placebo for 48 weeks, with lifestyle intervention in both groups. Continued treatment produced further average weight loss; the placebo-switch group regained weight. Gastrointestinal events were more frequent with continued treatment. This selected-participant injection trial does not predict how much or how quickly weight returns after stopping oral tablets, or supply individual stopping, restarting or lifelong-treatment instructions. [S14]¹⁴

Facts to compare

Open the source-bound fact recap (8 rows)

Source-bound facts from this guide
Question	Published fact	Evidence
Cost	> Quick answer: If you are researching how to get oral GLP-1 medicines, start with a clinician, identify the exact prescription product, then confirm coverage and pharmacy fulfilment. Wegovy tablets, Foundayo and diabetes-labeled semaglutide tablets have different indications and instructions. An online consultation or advertised price does not establish personal eligibility. [S1][S2][S3][S4]	Mapped claim
Product status	The current manufacturer-hosted US labels describe several oral products. Wegovy tablets contain semaglutide. Foundayo tablets contain orforglipron. The combined diabetes prescribing information covers Rybelsus and Ozempic tablets, which also contain semaglutide. These names do not establish identical indications, strengths or administration instructions. Prescribing information, physical page 1 of each document. [S1][S2][S3]	Mapped claim
Product status	\| Foundayo tablets \| With a reduced-calorie diet and increased physical activity, the label describes long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition. This is the orforglipron product, not semaglutide. Physical page 1. [S3] \|	Mapped claim
Product status	\| Rybelsus and Ozempic tablets \| Their combined label describes glycemic control with diet and exercise in adults with type 2 diabetes, and reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. Physical page 1. [S2] \|	Mapped claim
Product status	Ask the clinician to write down the product name and formulation when discussing options. “Ozempic” without the word tablet or injection can leave a practical ambiguity; the current combined tablet label explicitly distinguishes tablets from injections. It also states that Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis. Do not convert between them using the number printed on a package. Combined tablet label, physical page 1. [S2]	Mapped claim
Product status	Wegovy's combined label likewise separates tablet and injection indications. Its injection section includes pediatric and liver-disease indications that are not repeated in the tablet indication section. A general page about the brand can therefore be too broad for an oral-product question. Ask which exact formulation and indication the clinician is discussing. Wegovy label, physical page 1. [S1]	Mapped claim
Product status	The captured competitor explainer's product-list takeaway names Rybelsus, Wegovy pill and Foundayo. That describes its wording, not a medical inventory inferred from headings. Separately, the primary diabetes label identifies Ozempic tablets as well as Rybelsus. [S11][S2]	Mapped claim
Product status	Prepare a private medication list and questions for the clinical appointment, including other prescriptions, supplements and relevant medical history. The labels describe interactions and contraindications that require product-specific assessment. For example, the semaglutide labels discuss possible effects on other oral medicines, while Foundayo's label also identifies specific drug-interaction categories. Physical page 1 of each label. [S1][S2][S3]	Mapped claim

Quick evidence check

What the sources establish

Uses current primary evidence.
Separates verified facts from unknowns.
Maps decision-bearing claims to captured source text.

What still needs verification

Terms, prices, labels, and coverage can change.
Individual outcomes and eligibility cannot be inferred from general evidence.
The page cannot replace clinician, plan, or pharmacy verification.

Sources and what they support

Novo NordiskSupports: > **Quick answer:** If you are researching how to get oral GLP-1 medicines, start with a clinician, identify the exact prescription product, then confirm coverage and pharmacy fulfilment. Wegovy tablets, Foundayo and diabetes-labeled semaglutide tablets have different indications and instructions. An online consultation or advertised price does not establish personal eligibility. [S1][S2][S3][S4] · The current manufacturer-hosted US labels describe several oral products. Wegovy tablets contain semaglutide. Foundayo tablets contain orforglipron. The combined diabetes prescribing information covers Rybelsus and Ozempic tablets, which also contain semaglutide. These names do not establish identical indications, strengths or administration instructions. **Prescribing information, physical page 1 of each document.** [S1][S2][S3] · | Wegovy tablets | With a reduced-calorie diet and increased physical activity, the tablets are indicated for long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition; a separate indication concerns major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Physical page 1. [S1] | · Wegovy's combined label likewise separates tablet and injection indications. Its injection section includes pediatric and liver-disease indications that are not repeated in the tablet indication section. A general page about the brand can therefore be too broad for an oral-product question. Ask which exact formulation and indication the clinician is discussing. **Wegovy label, physical page 1.** [S1] · Prepare a private medication list and questions for the clinical appointment, including other prescriptions, supplements and relevant medical history. The labels describe interactions and contraindications that require product-specific assessment. For example, the semaglutide labels discuss possible effects on other oral medicines, while Foundayo's label also identifies specific drug-interaction categories. **Physical page 1 of each label.** [S1][S2][S3] · An oral formulation does not remove the need for a clinical risk review. Wegovy and the Rybelsus/Ozempic tablet label contain boxed warnings about thyroid C-cell tumors observed with semaglutide in rodents, with human relevance not determined. They list personal or family history of medullary thyroid carcinoma and MEN 2 among contraindications, alongside the specified hypersensitivity restrictions. **Physical page 1 of the respective labels.** [S1][S2] · The labels also describe significant gastrointestinal, pancreatic, gallbladder, kidney, hypoglycemia and hypersensitivity risks or precautions, with product-specific wording. These summaries are not the complete safety information and do not determine whether a reader can take a medicine. Ask the clinician to review the complete current label and explain which warnings are relevant to your history. **Physical page 1 of each document.** [S1][S2][S3] · Pregnancy, breastfeeding, planned procedures and other medicines belong in that conversation. The labels contain different reproductive and procedural precautions; they should not be compressed into a universal instruction about stopping, switching or timing medicines. We do not provide an individualized plan for any of those situations. **Physical page 1 of each label.** [S1][S2][S3] · A contraindication is not the same heading as a warning or precaution. For example, the labels place personal or family history of medullary thyroid carcinoma and MEN 2 in the contraindications section, while discussing several other conditions under warnings and precautions. A comparison article should not silently move a condition between those categories or replace the named thyroid-cancer type with every possible thyroid diagnosis. **Physical page 1 of the respective labels.** [S1][S2][S3] · The current Rybelsus/Ozempic tablet label expressly warns against milligram-for-milligram substitution. Wegovy's label has separate tablet and injection instructions. These are concrete reasons not to infer a replacement regimen from a similar active ingredient or a similar number on a box. **Diabetes tablet and Wegovy labels, physical page 1.** [S1][S2] · The labels differ in how tablets are taken. Wegovy and the Rybelsus/Ozempic tablet label describe morning administration on an empty stomach with water and a waiting period before food, beverages or other oral medicines. Foundayo's label describes once-daily use with or without food. These are product-label distinctions to discuss, not a recommendation to choose one medicine over another. **Physical page 1 of each label.** [S1][S2][S3] · Both contain semaglutide, but the current labels describe different products and indications. Wegovy tablets have adult weight-management and specified cardiovascular indications; the combined Rybelsus/Ozempic tablet label describes type 2 diabetes and its specified cardiovascular population. **Physical page 1 of both labels.** [S1][S2] · That conclusion is not established here. The current oral labels contain significant warnings, contraindications and different administration requirements. Discuss the product-specific balance and practical instructions with the clinician rather than inferring safety from the absence of an injection. **Label highlights, physical page 1.** [S1][S2][S3] · Wegovy-tablet and Foundayo labels describe reducing excess body weight and maintaining weight reduction long term. They do not establish a universal short course or an individual treatment duration. **Physical page 1 of both labels.** [S1][S3]Novo Nordisk — PDF documentcurrent as of 2026-10-09
Novo NordiskSupports: > **Quick answer:** If you are researching how to get oral GLP-1 medicines, start with a clinician, identify the exact prescription product, then confirm coverage and pharmacy fulfilment. Wegovy tablets, Foundayo and diabetes-labeled semaglutide tablets have different indications and instructions. An online consultation or advertised price does not establish personal eligibility. [S1][S2][S3][S4] · The current manufacturer-hosted US labels describe several oral products. Wegovy tablets contain semaglutide. Foundayo tablets contain orforglipron. The combined diabetes prescribing information covers Rybelsus and Ozempic tablets, which also contain semaglutide. These names do not establish identical indications, strengths or administration instructions. **Prescribing information, physical page 1 of each document.** [S1][S2][S3] · | Rybelsus and Ozempic tablets | Their combined label describes glycemic control with diet and exercise in adults with type 2 diabetes, and reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. Physical page 1. [S2] | · Ask the clinician to write down the product name and formulation when discussing options. “Ozempic” without the word tablet or injection can leave a practical ambiguity; the current combined tablet label explicitly distinguishes tablets from injections. It also states that Rybelsus and Ozempic tablets are not substitutable on a milligram-for-milligram basis. Do not convert between them using the number printed on a package. **Combined tablet label, physical page 1.** [S2] · The captured competitor explainer's product-list takeaway names Rybelsus, Wegovy pill and Foundayo. That describes its wording, not a medical inventory inferred from headings. Separately, the primary diabetes label identifies Ozempic tablets as well as Rybelsus. [S11][S2] · Prepare a private medication list and questions for the clinical appointment, including other prescriptions, supplements and relevant medical history. The labels describe interactions and contraindications that require product-specific assessment. For example, the semaglutide labels discuss possible effects on other oral medicines, while Foundayo's label also identifies specific drug-interaction categories. **Physical page 1 of each label.** [S1][S2][S3] · An oral formulation does not remove the need for a clinical risk review. Wegovy and the Rybelsus/Ozempic tablet label contain boxed warnings about thyroid C-cell tumors observed with semaglutide in rodents, with human relevance not determined. They list personal or family history of medullary thyroid carcinoma and MEN 2 among contraindications, alongside the specified hypersensitivity restrictions. **Physical page 1 of the respective labels.** [S1][S2] · The labels also describe significant gastrointestinal, pancreatic, gallbladder, kidney, hypoglycemia and hypersensitivity risks or precautions, with product-specific wording. These summaries are not the complete safety information and do not determine whether a reader can take a medicine. Ask the clinician to review the complete current label and explain which warnings are relevant to your history. **Physical page 1 of each document.** [S1][S2][S3] · Pregnancy, breastfeeding, planned procedures and other medicines belong in that conversation. The labels contain different reproductive and procedural precautions; they should not be compressed into a universal instruction about stopping, switching or timing medicines. We do not provide an individualized plan for any of those situations. **Physical page 1 of each label.** [S1][S2][S3] · A contraindication is not the same heading as a warning or precaution. For example, the labels place personal or family history of medullary thyroid carcinoma and MEN 2 in the contraindications section, while discussing several other conditions under warnings and precautions. A comparison article should not silently move a condition between those categories or replace the named thyroid-cancer type with every possible thyroid diagnosis. **Physical page 1 of the respective labels.** [S1][S2][S3] · The current Rybelsus/Ozempic tablet label expressly warns against milligram-for-milligram substitution. Wegovy's label has separate tablet and injection instructions. These are concrete reasons not to infer a replacement regimen from a similar active ingredient or a similar number on a box. **Diabetes tablet and Wegovy labels, physical page 1.** [S1][S2] · The labels differ in how tablets are taken. Wegovy and the Rybelsus/Ozempic tablet label describe morning administration on an empty stomach with water and a waiting period before food, beverages or other oral medicines. Foundayo's label describes once-daily use with or without food. These are product-label distinctions to discuss, not a recommendation to choose one medicine over another. **Physical page 1 of each label.** [S1][S2][S3] · Both contain semaglutide, but the current labels describe different products and indications. Wegovy tablets have adult weight-management and specified cardiovascular indications; the combined Rybelsus/Ozempic tablet label describes type 2 diabetes and its specified cardiovascular population. **Physical page 1 of both labels.** [S1][S2] · That conclusion is not established here. The current oral labels contain significant warnings, contraindications and different administration requirements. Discuss the product-specific balance and practical instructions with the clinician rather than inferring safety from the absence of an injection. **Label highlights, physical page 1.** [S1][S2][S3] · The cited trials studied defined regimens and populations; they are not a personal prescribing plan. In particular, the combined Rybelsus/Ozempic tablet label rejects milligram-for-milligram substitution. Take switching or regimen questions to the prescriber and pharmacist. **Combined tablet label, physical page 1.** [S2][S7][S8][S9]Novo Nordisk — PDF documentcurrent as of 2026-10-09
Eli LillySupports: > **Quick answer:** If you are researching how to get oral GLP-1 medicines, start with a clinician, identify the exact prescription product, then confirm coverage and pharmacy fulfilment. Wegovy tablets, Foundayo and diabetes-labeled semaglutide tablets have different indications and instructions. An online consultation or advertised price does not establish personal eligibility. [S1][S2][S3][S4] · The current manufacturer-hosted US labels describe several oral products. Wegovy tablets contain semaglutide. Foundayo tablets contain orforglipron. The combined diabetes prescribing information covers Rybelsus and Ozempic tablets, which also contain semaglutide. These names do not establish identical indications, strengths or administration instructions. **Prescribing information, physical page 1 of each document.** [S1][S2][S3] · | Foundayo tablets | With a reduced-calorie diet and increased physical activity, the label describes long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition. This is the orforglipron product, not semaglutide. Physical page 1. [S3] | · Prepare a private medication list and questions for the clinical appointment, including other prescriptions, supplements and relevant medical history. The labels describe interactions and contraindications that require product-specific assessment. For example, the semaglutide labels discuss possible effects on other oral medicines, while Foundayo's label also identifies specific drug-interaction categories. **Physical page 1 of each label.** [S1][S2][S3] · Foundayo also has a boxed warning and contraindications involving personal or family history of medullary thyroid carcinoma and MEN 2. Its warning is not identical to semaglutide's: it explains that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, while the human relevance of GLP-1-receptor-dependent rodent findings remains undetermined. Avoid collapsing those distinct label statements into one claim about all drugs. **Foundayo label, physical page 1.** [S3] · The labels also describe significant gastrointestinal, pancreatic, gallbladder, kidney, hypoglycemia and hypersensitivity risks or precautions, with product-specific wording. These summaries are not the complete safety information and do not determine whether a reader can take a medicine. Ask the clinician to review the complete current label and explain which warnings are relevant to your history. **Physical page 1 of each document.** [S1][S2][S3] · Pregnancy, breastfeeding, planned procedures and other medicines belong in that conversation. The labels contain different reproductive and procedural precautions; they should not be compressed into a universal instruction about stopping, switching or timing medicines. We do not provide an individualized plan for any of those situations. **Physical page 1 of each label.** [S1][S2][S3] · A contraindication is not the same heading as a warning or precaution. For example, the labels place personal or family history of medullary thyroid carcinoma and MEN 2 in the contraindications section, while discussing several other conditions under warnings and precautions. A comparison article should not silently move a condition between those categories or replace the named thyroid-cancer type with every possible thyroid diagnosis. **Physical page 1 of the respective labels.** [S1][S2][S3] · The labels differ in how tablets are taken. Wegovy and the Rybelsus/Ozempic tablet label describe morning administration on an empty stomach with water and a waiting period before food, beverages or other oral medicines. Foundayo's label describes once-daily use with or without food. These are product-label distinctions to discuss, not a recommendation to choose one medicine over another. **Physical page 1 of each label.** [S1][S2][S3] · That conclusion is not established here. The current oral labels contain significant warnings, contraindications and different administration requirements. Discuss the product-specific balance and practical instructions with the clinician rather than inferring safety from the absence of an injection. **Label highlights, physical page 1.** [S1][S2][S3] · Foundayo contains a different active ingredient, orforglipron, whose label also identifies it as a GLP-1 receptor agonist. Sharing a receptor class does not make its instructions or evidence interchangeable with semaglutide tablets. **Foundayo label, physical page 1.** [S3] · Wegovy-tablet and Foundayo labels describe reducing excess body weight and maintaining weight reduction long term. They do not establish a universal short course or an individual treatment duration. **Physical page 1 of both labels.** [S1][S3]Eli Lilly — PDF documentcurrent as of 2026-10-09
Novo NordiskSupports: These trials were not a head-to-head comparison of every pill and injection named on this page. Do not rank products by placing percentages from different trials side by side without considering the populations, design and analysis. The captured OASIS 4 registration and protocol identify the planned study; observed outcomes here come from the published original report, not from the mere existence of a registration. [S7][S8][S9][S10]Novo Nordisk — PDF documentcurrent as of 2026-10-09
Novo NordiskSupports: > **Quick answer:** If you are researching how to get oral GLP-1 medicines, start with a clinician, identify the exact prescription product, then confirm coverage and pharmacy fulfilment. Wegovy tablets, Foundayo and diabetes-labeled semaglutide tablets have different indications and instructions. An online consultation or advertised price does not establish personal eligibility. [S1][S2][S3][S4] · Wegovy's official access page describes three practical stages: talk to a doctor, investigate savings and fill the prescription. It explicitly states that Wegovy requires a prescription and points readers toward both in-person and telehealth care resources. Those resources are navigation options, not an independent assessment by Clinic Scout of any listed service. [S4] · The official Wegovy access page describes filling a prescription through a local pharmacy or using delivery, subject to terms. NovoCare's pharmacy page describes having the prescriber send the prescription and looking for a confirmation message. These are reported fulfilment pathways, not proof that a particular pharmacy has your product available or that a shipment has been approved. [S4][S5] · The official access material says Wegovy requires a prescription, and NovoCare says the products on its pharmacy page require one. Start with a clinical evaluation rather than treating a sales page as a prescription decision. This guide does not endorse sellers offering a shortcut around that process. [S4][S5] · No personal prescription approval is established by this guide. The access pathway begins with a clinician, and the medicine remains prescription-only. Ask the service what an evaluation covers and what happens when the requested medicine is not prescribed; we have not verified a universal refund or outcome policy. [S4]Novo Nordisk — published pagecurrent as of 2026-10-09
Novo NordiskSupports: NovoCare Pharmacy's published Wegovy-tablet self-pay prices were **current as of 2026-10-09**. The amounts below are medication prices for the stated tablet strength and supply, not a personal quote or total care cost. [S5] · For a savings offer, check the official product-specific terms separately from the self-pay prices above. NovoCare's page distinguishes insurance and self-pay pathways; these payment routes do not have interchangeable conditions. [S5] · The official Wegovy access page describes filling a prescription through a local pharmacy or using delivery, subject to terms. NovoCare's pharmacy page describes having the prescriber send the prescription and looking for a confirmation message. These are reported fulfilment pathways, not proof that a particular pharmacy has your product available or that a shipment has been approved. [S4][S5] · The official access material says Wegovy requires a prescription, and NovoCare says the products on its pharmacy page require one. Start with a clinical evaluation rather than treating a sales page as a prescription decision. This guide does not endorse sellers offering a shortcut around that process. [S4][S5] · No individual cost is verified here. The manufacturer pharmacy page separates payment routes and attaches conditions to advertised amounts. Ask for the exact supply, product, payment arrangement and next-fill terms, plus any service charges quoted separately. [S5] · | 1.5 mg | $149 for one bottle of 30 tablets. [S5] | · | 4 mg | $199 for one bottle of 30 tablets. [S5] | · | 9 mg or 25 mg | $299 for one bottle of 30 tablets. [S5] | · Eligibility and restrictions apply. Novo Nordisk reserves the right to modify or cancel the programme at any time. These are the published 2026-10-09 terms, not a guarantee of your next fill; separately quoted consultation, membership or other care charges are not established by this medication-price table. [S5]Novo Nordisk — published pagecurrent as of 2026-10-09
Yale MedicineSupports: Yale Medicine's access overview says patients can begin with a primary care clinician, an obesity-medicine specialist or, in some cases, a telehealth provider. It emphasizes experience and follow-up over time. That supports asking about continuity of care rather than choosing solely by the shortest advertised appointment time. It does not establish the licensing, availability or quality of a particular online provider. [S6] · Also ask what follow-up is included, who reviews tolerability or other concerns, and how a future change in insurance or supply would be handled. Yale Medicine's access overview emphasizes a clinician who can follow the patient over time. That supports planning for communication beyond the first visit; it is not proof that every service provides the same level of support. [S6]Yale Medicine — published pagecurrent as of 2026-10-09
PubMed original report: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.Supports: The OASIS 4 randomized, double-blind trial studied oral semaglutide 25 mg against placebo with lifestyle interventions in adults with overweight or obesity without diabetes. At the week-64 assessment, the oral-semaglutide group had greater mean weight reduction, but gastrointestinal adverse events were more common than with placebo. The study was funded by Novo Nordisk. This qualitative result applies to that product, population, comparison and study period; it is not an individual forecast. [S7] · These trials were not a head-to-head comparison of every pill and injection named on this page. Do not rank products by placing percentages from different trials side by side without considering the populations, design and analysis. The captured OASIS 4 registration and protocol identify the planned study; observed outcomes here come from the published original report, not from the mere existence of a registration. [S7][S8][S9][S10] · The cited trials studied defined regimens and populations; they are not a personal prescribing plan. In particular, the combined Rybelsus/Ozempic tablet label rejects milligram-for-milligram substitution. Take switching or regimen questions to the prescriber and pharmacist. **Combined tablet label, physical page 1.** [S2][S7][S8][S9]PubMed original report: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. — published pagecurrent as of 2026-10-09
PubMed original report: Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.Supports: OASIS 1 studied a different oral-semaglutide amount, 50 mg, for 68 weeks in adults without type 2 diabetes and also reported greater weight reduction than placebo alongside more gastrointestinal adverse events. OASIS 2 used 50 mg in an East Asian population with different entry criteria and included participants with type 2 diabetes. Those studies do not turn a 50 mg research regimen into instructions for a currently prescribed product. [S8][S9] · These trials were not a head-to-head comparison of every pill and injection named on this page. Do not rank products by placing percentages from different trials side by side without considering the populations, design and analysis. The captured OASIS 4 registration and protocol identify the planned study; observed outcomes here come from the published original report, not from the mere existence of a registration. [S7][S8][S9][S10] · The cited trials studied defined regimens and populations; they are not a personal prescribing plan. In particular, the combined Rybelsus/Ozempic tablet label rejects milligram-for-milligram substitution. Take switching or regimen questions to the prescriber and pharmacist. **Combined tablet label, physical page 1.** [S2][S7][S8][S9]PubMed original report: Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. — published pagecurrent as of 2026-10-09
PubMed original report: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.Supports: OASIS 1 studied a different oral-semaglutide amount, 50 mg, for 68 weeks in adults without type 2 diabetes and also reported greater weight reduction than placebo alongside more gastrointestinal adverse events. OASIS 2 used 50 mg in an East Asian population with different entry criteria and included participants with type 2 diabetes. Those studies do not turn a 50 mg research regimen into instructions for a currently prescribed product. [S8][S9] · These trials were not a head-to-head comparison of every pill and injection named on this page. Do not rank products by placing percentages from different trials side by side without considering the populations, design and analysis. The captured OASIS 4 registration and protocol identify the planned study; observed outcomes here come from the published original report, not from the mere existence of a registration. [S7][S8][S9][S10] · The cited trials studied defined regimens and populations; they are not a personal prescribing plan. In particular, the combined Rybelsus/Ozempic tablet label rejects milligram-for-milligram substitution. Take switching or regimen questions to the prescriber and pharmacist. **Combined tablet label, physical page 1.** [S2][S7][S8][S9]PubMed original report: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. — published pagecurrent as of 2026-10-09
RoSupports: The captured competitor explainer's product-list takeaway names Rybelsus, Wegovy pill and Foundayo. That describes its wording, not a medical inventory inferred from headings. Separately, the primary diabetes label identifies Ozempic tablets as well as Rybelsus. [S11][S2]Ro — published pagecurrent as of 2026-10-09
Novo NordiskSupports: Semaglutide binds to and activates the GLP-1 receptor. The diabetes-tablet label describes glucose-dependent insulin stimulation and glucagon reduction, with a minor delay in early post-meal gastric emptying. This explains the mechanism, not an individual's response. **Combined tablet label, section 12.1, physical page 6.** [S12] · The combined diabetes label bases Rybelsus and Ozempic-tablet glycemic effectiveness on controlled Rybelsus studies in adults with type 2 diabetes. In its 26-week double-blind randomized monotherapy trial, adults inadequately controlled with diet and exercise received semaglutide tablets or placebo; the 7 mg and 14 mg study groups had statistically significant HbA1c reductions versus placebo. These are diabetes study regimens, not strength-selection, conversion or weight-loss instructions. **Combined tablet label, sections 14.1–14.2, physical page 7.** [S12]Novo Nordisk — PDF documentcurrent as of 2026-10-09
Centers for Medicare & Medicaid ServicesSupports: CMS's Medicare GLP-1 Bridge information, checked **2026-10-09**, describes a July 1, 2026–December 31, 2027 demonstration outside ordinary Part D coverage and payment flows. Listed weight-management products include Wegovy tablets and Foundayo. Eligible Part D plan types, clinical criteria, a prescription and prescriber prior authorization are required; Medicare enrollment alone does not establish eligibility. [S13] · CMS directs Part D-covered indications, such as type 2 diabetes, through the Part D plan instead of the Bridge. Identify the oral product, indication and programme together: conditional Bridge access is neither universal oral-GLP-1 coverage nor a manufacturer self-pay offer. [S13]Centers for Medicare & Medicaid Services — published pagecurrent as of 2026-10-09
STEP 4 original trial report via PubMedSupports: In the STEP 4 randomized withdrawal trial, adults with overweight or obesity without diabetes who reached subcutaneous semaglutide 2.4 mg weekly after a 20-week run-in continued treatment or switched to placebo for 48 weeks, with lifestyle intervention in both groups. Continued treatment produced further average weight loss; the placebo-switch group regained weight. Gastrointestinal events were more frequent with continued treatment. This selected-participant injection trial does not predict how much or how quickly weight returns after stopping oral tablets, or supply individual stopping, restarting or lifelong-treatment instructions. [S14]STEP 4 original trial report via PubMed — published pagecurrent as of 2026-10-09

Guide disclosures

Questions about this evidence record

What does this guide establish?

What does this guide not determine?

This evidence guide is educational and is not medical advice, diagnosis, individualized eligibility screening, or a treatment recommendation.

Keep reading

Continue the source trail.

Trimi vs yourEra: look past the shared $99 starting price

Both programs displayed compounded semaglutide from $99 per month on the checked date, but that shared number does not make the offers equivalent. Trimi attached its lowest prices to an annual plan and stated free overnight shipping. yourEra listed compounded semaglutide from $99 and compounded tirzepatide from $169, with free shipping and ongoing care-team messaging. Compare the amount due, minimum term, exact product, included care, and current checkout terms before paying.

Gala vs Shed: compare the full terms, not a $20 headline gap

Gala displayed compounded GLP-1/GIP access from $179 per month with a yearly subscription. Shed displayed a GLP-1 injection program from $199 per month, said medication or dose can change the price, and described insurance or cash-pay options. The visible $20 difference is not a complete cost comparison because the term, product, service scope, and payment pathway differ.

Found vs Trimi: two different ways to pay for an online program

Found documents an insurance-help pathway through a free insurance check and work with multiple U.S. carriers, while Trimi documents a self-pay offer whose lowest prices require an annual plan. Found does not guarantee coverage, and its medication and membership or care charges may be separate. Compare Found’s plan-specific responsibility with Trimi’s complete minimum-term obligation before choosing between the payment structures.